Susceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, a Novel Helicase-Primase Inhibitor

Kiyomitsu Katsumata, Adriana Weinberg, Koji Chono, Shoji Takakura, Toru Kontani, and Hiroshi Suzuki

Department of Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan; and University of Colorado Hospital and Departments of Pediatrics, Medicine and Pathology, University of Colorado, Denver, Aurora, Colorado, USA

ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. To evaluate the anti-HSV activity of ASP2151, susceptibility testing was performed on viruses isolated from patients participating in a placebo- and valacyclovir-controlled proof-of-concept phase II study for recurrent genital herpes. A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected. ASP2151 inhibited HSV-1 and HSV-2 replication with mean 50% effective concentrations (EC50s) of 0.043 and 0.069 μM, whereas ACV exhibited mean EC50s of 2.1 and 3.2 μM, respectively. Notably, the susceptibilities of HSV isolates to ASP2151 and ACV were not altered after dosing with the antiviral agents. Taken together, these results demonstrate that ASP2151 inhibits the replication of HSV clinical isolates more potently than ACV, and HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients.

Genital herpes infections are caused by herpes simplex virus type 1 (HSV-1) or HSV-2, which are widely prevalent pathogens belonging to the human herpesvirus family, and are characterized by the formation of painful vesicles or small, grouped ulcers in the genital region. After primary infection, HSV establishes latency in sensory ganglia, which is followed by recurrent episodes of reactivation (20). HSV subtypes differ with respect to epidemiology, natural history, and propensity for recurrence (3, 15); for instance, HSV-1 genital infections are typically milder and less prone to recurrence than those of HSV-2 (1, 16, 24, 26, 27), whereas the latter virus is the more frequent cause of genital herpes (11, 17). Although no effective treatment exists for the eradication of genital herpes, several antiviral drugs are available to treat outbreak episodes and minimize disease symptoms.

Since the late 1970s, several synthetic nucleoside analogues, including acyclovir (ACV), penciclovir, valacyclovir (VCV), and famciclovir, have been developed for treating HSV infections (9, 10). These antiviral agents, as well as ganciclovir and valganciclovir, which also display anti-HSV activity, function as viral DNA polymerase inhibitors and, to some extent, DNA chain terminators during viral DNA replication but require prior phosphorylation by viral thymidine kinase (TK) and cellular kinases to form active triphosphates. Hence, HSV can develop cross-resistance to nucleoside analogues through mutation of viral TK and/or DNA polymerase genes (18). Because viral TK is not essential for viral replication, TK-deficient HSV mutants are readily detectable among pools of wild-type HSV, at frequencies ranging from 10⁻⁴ to 10⁻³ (2, 8, 19, 21). Since the most commonly isolated ACV-resistant variants of HSV have a TK-deficient phenotype, exposure to ACV might promote the selection and enrichment of ACV-resistant HSV in the clinical setting. Currently, foscarnet and cidofovir are the only antiviral agents approved for the treatment of severe HSV infections that do not require TK-mediated phosphorylation. However, both drugs are available only for parenteral use, can be difficult to tolerate, and have potentially serious side effects, including renal failure. Thus, the development of a novel class of anti-HSV agents with a mechanism of action that targets a viral protein essential for replication is desirable.

ASP2151 is a nonnucleoside, oxadiazol-phenyl-containing drug that targets the helicase-primase complex of HSV-1, HSV-2, and varicella-zoster virus (VZV) (6). Since this protein complex is essential for HSV DNA synthesis, helicase-primase inhibitors such as ASP2151 represent a potentially effective treatment option for genital herpes. Notably, ASP2151 has demonstrated more-potent in vitro antiviral activity than ACV against a limited number of laboratory stocks and clinically isolated strains of HSV-1, HSV-2, and VZV (6). In addition, ASP2151 has excellent oral bioavailability and potent anti-HSV activities in animal models (6, 14, 23).

The aim of the present study was to evaluate the antiviral activities of ASP2151 against a broad range of clinical HSV isolates obtained from patients participating in a placebo- and VCV-controlled proof-of-concept study of ASP2151 (3-day treatment course) for recurrent genital herpes (23). In addition, we also monitored changes in the susceptibility of HSV isolates to ASP2151 before and after the short-term dosing of patients with ASP2151.

MATERIALS AND METHODS

Antiviral compounds. ASP2151 (international nonproprietary name, amenamevir) was synthesized at Astellas Pharma, Inc. (Tokyo, Japan). ACV was purchased from a commercial supplier (Sigma-Aldrich, St. Louis, MO).

Clinical specimens. HSVs were isolated from genital herpes patients enrolled in a phase II, double-blinded, multicenter, randomized, active-placebo-controlled proof-of-concept study at 26 sites throughout the United States between June 2007 and August 2008 (23). A signed informed consent form was obtained from each patient before the initiation of any study-specific procedure. A total of 156 HSV isolates (5 HSV-1 and
151 HSV-2 isolates) were recovered from the positive viral cultures of genital swab samples collected before the dosing of patients with placebo, VCV (500 mg twice daily for 3 days), or ASP2151 (100, 200, or 400 mg once daily for 3 days or 1,200 mg one-shot). Of these patients, 106 HSV isolates (3 HSV-1 and 103 HSV-2 isolates) were also collected from the same patients within or after the 3-day treatment period.

PRA. HSV isolates successfully obtained from the first (average of 0.6 h before treatment) and last (average of 46.8 h after the initiation of treatment) positive culture for each patient were tested for sensitivity to ASP2151 and ACV using a plaque reduction assay (PRA), as previously described (25). Briefly, human embryonic lung fibroblast (HELF) cells were seeded into 12-well plates (2 × 10^5 cells/well) and incubated at 37°C until the cells formed a monolayer. After removal of the growth medium, the cells were infected with HSV-1 or HSV-2 (50 to 100 PFU/well), and the plates were then incubated for 1 h at 37°C. After the viral inocula were aspirated, cells were treated with the test compound until clear plaques appeared. The cells were then fixed with 10% formalin in phosphate-buffered saline and stained with a 0.8% crystal violet solution. The number of plaques present in each well was determined by counting under a microscope. The 50% effective concentration (EC50), which is the concentration to reduce the plaque number by 50%, was calculated using linear regression analysis. The antiviral activity of ASP2151 was fitted to the sampling time of the respective isolates using the linear regression program of GraphPad Prism (GraphPad Software, San Diego, CA). ACV-
TABLE 1 Susceptibilities to acyclovir and ASP2151 of clinical isolates obtained from patients treated with antiviral agents

<table>
<thead>
<tr>
<th>Antiviral agent administered and dose (mg)</th>
<th>No. of isolates*</th>
<th>Acyclovir EC₅₀ (µM)</th>
<th>ASP2151 EC₅₀ (µM)</th>
<th>Result for**:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Pre</td>
<td>Post</td>
<td>P value**</td>
</tr>
<tr>
<td>Placebo</td>
<td>26</td>
<td>3.3 ± 0.4</td>
<td>3.9 ± 0.5</td>
<td>0.1944</td>
</tr>
<tr>
<td>Valacyclovir, 500</td>
<td>13</td>
<td>2.2 ± 0.2</td>
<td>3.0 ± 0.6</td>
<td>0.3043</td>
</tr>
<tr>
<td>ASP2151</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>15</td>
<td>2.6 ± 0.3</td>
<td>3.8 ± 0.6</td>
<td>0.0132</td>
</tr>
<tr>
<td>200</td>
<td>16</td>
<td>2.8 ± 0.3</td>
<td>3.0 ± 0.6</td>
<td>0.7497</td>
</tr>
<tr>
<td>400</td>
<td>16</td>
<td>3.2 ± 0.6</td>
<td>3.1 ± 0.4</td>
<td>0.8904</td>
</tr>
<tr>
<td>1,200</td>
<td>20</td>
<td>3.1 ± 0.3</td>
<td>3.9 ± 0.5</td>
<td>0.1324</td>
</tr>
</tbody>
</table>

*Number of isolates that were collected both before and after the first dosing of patients.

**Data represent the mean EC₅₀ and standard errors of triplicate determinations for viruses isolated from patients before (Pre) and after (Post) dosing.

c Comparisons between pre- and postdosing EC₅₀s were performed using the paired Student t test.

and ASP2151-sensitive and resistant HSV controls were repeatedly tested for validation. A sensitive clinical isolate (sensitive control) was included in each run. ACV resistance was defined by an EC₅₀ of ≥11.1 µM (2.5 µg/ml) and a ≥4-fold increase over the EC₅₀ for the sensitive control included in the run. Since there are no recognized in vitro breakpoints for defining resistance to ASP2151, we set provisional guidelines for this study. Preexisting resistance to ASP2151 was defined by an EC₅₀ ≥4-fold increased over that for the sensitive control and greater than the mean + 3 standard deviations (SD) based on aggregate data for the sensitive control. Resistance associated with ASP2151 treatment was defined by satisfying the criteria described above and by a ≥4-fold increase in the EC₅₀ over the EC₅₀ against the pretherapy isolate obtained from any given subject.

Statistical analyses. Statistical analyses were performed using the SAS software program (SAS Institute, Carey, NC), and a P value of <0.05 was considered statistically significant. In the PRA, results were analyzed using the paired Student t test for comparisons of samples obtained before and after dosing patients with antiviral agents.

RESULTS AND DISCUSSION

PRA analysis was performed to test the antiviral activities of ACV and ASP2151 against a total of 156 clinical HSV isolates (HSV-1, n = 5; HSV-2, n = 151). Figure 1 shows the susceptibilities to ACV and ASP2151 of HSV isolates obtained from predose subjects. The EC₅₀s (means ± standard errors [SE]) of ACV and ASP2151 against the HSV isolates were 2.1 ± 0.8 and 0.043 ± 0.011 µM, respectively, for HSV-1 and 3.2 ± 0.2 and 0.069 ± 0.003 µM, respectively, for HSV-2. The PRA results indicate that ASP2151 inhibits the replication of a broad range of clinical HSV isolates at concentrations lower than those of ACV. Importantly, no ASP2151- or ACV-resistant HSV clinical isolates were detected prior to the dosing of patients. The ratios of EC₅₀s for ASP2151 and ACV to data for the sensitive control ranged from 0.1 to 3.9 and 0.2 to 3.6, respectively.

We next investigated whether the susceptibilities of HSV isolates to the two antiviral agents were altered within or following the 3-day dosing period of patients with placebo (n = 26), VCV (500 mg; n = 13), or ASP2151 (100, 200, 400, and 1,200 mg; n = 15, 16, 16, and 20, respectively). The overall susceptibility of the HSV strains to ASP2151 and ACV was not altered after the dosing (P > 0.05) (Fig. 2). The mean antiviral activities of ASP2151 against the HSV isolates obtained from patients pre- and postdosing with ASP2151 (100, 200, 400, and 1,200 mg) did not significantly differ (P = 0.2243, 0.4402, 0.8034, and 0.2770, respectively) (Table 1). In addition, the HSV isolates from patients treated with VCV did not show significantly decreased susceptibility to ACV (Fig. 2 and Table 1). Although ASP2151 dosing did not result in significant alteration of susceptibility of HSV isolates to ACV (Fig. 2), a slight difference in the mean EC₅₀s of ACV was obtained between pre- and post-dosing with 100 mg ASP2151 (P = 0.013) (Table 1). However, since no dose dependency of ASP2151 was evident with regard to alteration on susceptibility to ACV, ASP2151 does not likely have the ability to select ACV resistance. Importantly, a trend toward resistance development with increasing duration of treatment also was not detected (Fig. 3). When the relationship between the antiviral activity of ASP2151 and sampling time for the HSV isolates was analyzed, the 95% confidence intervals for the slope of the plotted line determined using a linear regression model ranged from −0.0006 to 0.0003, −0.0005 to 0.0005, −0.001 to 0.0006, and −0.0003 to 0.0003 for isolates obtained from patients given 100, 200, 400, and 1,200 mg ASP2151, respectively. This analysis indicates that no correlation exists between the antiviral activity of ASP2151 and sampling time for the isolates. Together, these findings suggest that no ASP2151- or ACV-resistant HSV would be detected after the short-term treatment of recurrent genital herpes patients with the respective antiviral agents.

The emergence of highly virulent mutant HSV with resistance to antiviral drugs is of concern for the effective treatment of genital herpes. Although ACV-resistant mutants were previously detected at relatively high frequencies (10⁻⁴ to 10⁻³) in tissue culture (2,18, 19, 21), no resistant HSV was found among the clinical isolates in the present study. This finding is consistent with the fact that the reported incidence of ACV-resistant HSV has not significantly increased among immunocompetent patients despite the widespread use of ACV (5,18), although ACV resistance is problematic in immunocompromised patients, in which <5% of isolates are reported to be ACV resistant (7,12).

In *in vitro* studies, mutants resistant to the HSV helicase-primease inhibitor AIC316 (also called BAY 57-1293) were detected at 10 to 100 times the expected background frequency (<10⁻⁶) for 16% to 20% of clinical isolates following incubation in the presence of 0.8 to 3 µM AIC316 (4,22). However, no viral resistance to AIC316 was observed after 28 days of treatment in a phase II trial.
Involving genital herpes patients (13). In the present study, we also found that all clinical HSV isolates were susceptible to ASP2151, with no preexisting resistant variants detected, and that the overall susceptibility of the HSV strains to ASP2151 was not markedly altered after dosing (Fig. 1 and 2). We have shown that the frequency of ASP2151-resistant variants in \textit{in vitro} cell cultures is lower than that of ACV-resistant variants, and that the ASP2151-resistant strains exhibit lower growth ability than the parent strain (data not shown). Therefore, the ASP2151-resistant virus might not be isolated or may be difficult to select for after short-term treatment in the clinic. Based on our present findings and the literature cited above (5, 13, 18), preexisting variants resistant to ASP2151 are unlikely to be detected, and ASP2151 might not select for resistant HSV in immunocompetent patients with recurrent genital herpes. Nevertheless, further investigations are necessary to determine if resistant strains of HSV would be likely to emerge in the clinical setting, notably during long-term suppressive treatment for genital herpes.

In conclusion, our results demonstrate that the helicase-primase inhibitor ASP2151 prevented the replication of HSV clinical isolates more potently than ACV. Moreover, HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients.

\textbf{ACKNOWLEDGMENT}

This work was supported by and conducted at Astellas Pharma Inc.

\textbf{REFERENCES}


primase inhibitor, in a guinea pig model of genital herpes. Molecules 16:7210–7223.